Drugs / E8001
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT04609852 | Oct 2020 → Aug 2023 | — | Eisai Inc. | Completed | No outcome recorded |
Evidence & citations 5 cited values
Every value below carries the sentence it was read from. 2 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | E8001 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT04609852 ↗ |
| Action | Inhibit | “C5 siRNA-LNP completely suppressed C5 expression” PMID 35749284 ↗ Nov 2022 |
| Modality | Small interfering RNA (siRNA) | “a lipid nanoparticle (LNP) formulation of small-interfering RNA against complement C5 (C5 siRNA-LNP)” PMID 35749284 ↗ Nov 2022 |
| Route | Intravenous | “Intravenous infusion.” NCT04609852 ↗ |
| Target | C5 | “small-interfering RNA against complement C5 (C5 siRNA-LNP)” PMID 35749284 ↗ Nov 2022 |